Company commences Technegas trial in U.S.

11/20/2012 | ProactiveInvestors.co.au (Australia)

Cyclopharm has enrolled the first patient in a U.S. clinical trial involving its Technegas product, a gas inhaled by patients before imaging to improve detection of blood clots in the lungs. The multi-center study will eventually involve 750 patients and is expected to be completed in 18 months.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI